Rational approaches to developing an anti-disease vaccine against malaria.
Vaccination against pathogen toxins provides a rational approach to prevent morbidity and mortality, and is widely validated in the context of bacterial infections. A saccharide-conjugate vaccine targeting the malaria glycosylphosphatidylinositol toxin glycan could therefore prevent severe disease. This strategy could also reduce the risk posed by 'rebound' infections or immunopathology associated with other interventions.
Schofield
Louis
L
The Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade, Parkville, 3050 Victoria, Australia. schofield@wehi.edu.au
D000818:Animals; D003643:Death; D015195:Drug Design; D017261:Glycosylphosphatidylinositols / Q000737:chemistry / Q000276:immunology; D006801:Humans; D008288:Malaria / Q000378:metabolism / Q000503:physiopathology* / Q000517:prevention & control; D017780:Malaria Vaccines / Q000009:adverse effects / Q000276:immunology; D010961:Plasmodium / Q000378:metabolism*; D015800:Protozoan Proteins / Q000276:immunology; D012449:Safety; D014118:Toxins, Biological / Q000276:immunology / Q000378:metabolism
D017261:Glycosylphosphatidylinositols; D017780:Malaria Vaccines; D015800:Protozoan Proteins; D014118:Toxins, Biological